A Clinical Role of PET-MRI in Prostate Cancer?

被引:3
|
作者
Gammel, Michael C. M. [1 ]
Solari, Esteban L. [1 ]
Eiber, Matthias [1 ]
Rauscher, Isabel [1 ]
Nekolla, Stephan G. [1 ,2 ]
机构
[1] Tech Univ Munich, Sch Med, Dept Nucl Med, Klinikum Rechts Isar, Munich, Germany
[2] Tech Univ Munich, Sch Med, Dept Nucl Med, Klinikum Rechts Isar, Ismaningerstr 22, Munich, Germany
关键词
GA-68-LABELED PSMA LIGAND; ATTENUATION CORRECTION; DIAGNOSTIC-VALUE; QUANTITATIVE-EVALUATION; SCATTER CORRECTION; MEMBRANE ANTIGEN; PET/MRI; CLASSIFICATION; ACCURACY; ATLAS;
D O I
10.1053/j.semnuclmed.2023.08.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PET/MRI is a relevant application field for prostate cancer management, offering advan-tages in early diagnosis, staging, and therapy planning. Despite drawbacks such as higher costs, longer acquisition time, and the need for skilled personnel, the technical integration of PET and MRI provides valuable information for detecting primary tumors, identifying metastases, and characterizing the disease, leading to more accurate staging and personal-ized treatment strategies. However, PET/MRI adoption has been slow, but ongoing techno-logical advancements and AI integration might overcome challenges and improve clinical utility. As precision medicine gains importance in oncology, PET/MRI's multiparametric data can tailor treatment plans to individual patients, providing a comprehensive assess-ment of tumor biology and aggressiveness for more effective therapeutic strategies. Semin Nucl Med 54:132-140 (c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:132 / 140
页数:9
相关论文
共 50 条
  • [31] Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
    Glemser, P. A.
    Rotkopf, L. T.
    Ziener, C. H.
    Beuthien-Baumann, B.
    Weru, V
    Kopp-Schneider, A.
    Schlemmer, H. P.
    Dimitrakopoulou-Strauss, A.
    Sachpekidis, C.
    CANCER IMAGING, 2022, 22 (01)
  • [32] Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
    P. A. Glemser
    L. T. Rotkopf
    C. H. Ziener
    B. Beuthien-Baumann
    V. Weru
    A. Kopp-Schneider
    H. P. Schlemmer
    A. Dimitrakopoulou-Strauss
    C. Sachpekidis
    Cancer Imaging, 22
  • [33] First experiences with PET-MRI/CT in radiotherapy planning for cervical cancer
    Sophia Scharl
    Clara-Bianca Weidenbaecher
    Christine Hugo
    Christine E. Brambs
    Karina Knorr
    Stephanie E. Combs
    Lars Schüttrumpf
    Archives of Gynecology and Obstetrics, 2022, 306 : 1821 - 1828
  • [34] Role of FDG-PET in the Clinical Management of Paraneoplastic Neurological Syndrome: Detection of the Underlying Malignancy and the Brain PET-MRI Correlates
    Sandip Basu
    Abass Alavi
    Molecular Imaging and Biology, 2008, 10 : 131 - 137
  • [35] Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: Detection of the underlying malignancy and the brain PET-MRI correlates
    Basu, Sandip
    Alavi, Abass
    MOLECULAR IMAGING AND BIOLOGY, 2008, 10 (03) : 131 - 137
  • [36] First experiences with PET-MRI/CT in radiotherapy planning for cervical cancer
    Scharl, Sophia
    Weidenbaecher, Clara-Bianca
    Hugo, Christine
    Brambs, Christine E.
    Knorr, Karina
    Combs, Stephanie E.
    Schuettrumpf, Lars
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2022, 306 (05) : 1821 - 1828
  • [37] PET-MRI provides incremental value in patients with head and neck cancer
    Mehdikhani, Hossein
    Habib, Maria
    Gavane, Somali
    Ayache, Jad Bou
    Miles, Brett
    Som, Peter
    Kostakoglu, Lale
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [38] Evaluation of Prostate Cancer with PET/MRI
    Lindenberg, Liza
    Ahlman, Mark
    Turkbey, Baris
    Mena, Esther
    Choyke, Peter
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 : 111S - 116S
  • [39] FDG PET-MRI in the management of patients with muscle invasive bladder cancer
    Civelek, Ali
    Lin, Jeffrey
    Agarwal, Piyush
    Malayeri, Ashkan
    Apolo, Andrea
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [40] Prostate Cancer PET/MRI is not inferior to PET/CT
    Krome, Susanne
    AKTUELLE UROLOGIE, 2017, 48 (05) : 407 - 407